You just read:

Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis

News provided by

Mast Therapeutics, Inc.

Feb 22, 2016, 05:00 EST